Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.
Aberrant expression of the RON receptor tyrosine kinase, a member of the MET proto-oncogene family, contributes significantly to pancreatic cancer tumorigenesis and chemoresistance. Here we validate RON as a target for pancreatic cancer therapy using a novel anti-RON antibody Zt/g4-drug maytansinoid conjugates (Zt/g4-DM1) as a model for RON-targeted drug delivery to kill pancreatic cancer cells. In pancreatic cancer cell lines overexpressing RON, Zt/g4-DM1 rapidly induced receptor endocytosis, arrested cell cycle at G2/M phase, reduced cell viability, and subsequently caused massive cell death. These in vitro observations help to establish a correlation between the number of the cell surface RON receptors and the efficacy of Zt/g4-DM1 in reduction of cell viability. In mice, Zt/g4-DM1 pharmacokinetics in the linear dose range fitted into a two-compartment model with clearance in 0.21 ml/day/kg and terminal half-life at 6.05 days. These results helped to confirm a concentration-activity relationship for the BxPC-3 and other pancreatic cancer cell xenograft model with a tumoristatic dose at 3.02 mg/kg. Zt/g4-DM1 was effective in vivo against various xenograft PDAC growth but efficacy varied with individual cell lines. Combination of Zt/g4-DM1 with gemcitabine had a complete inhibition of xenograft pancreatic cancer growth. We conclude from these studies that increased RON expression in pancreatic cancer cells is a suitable targeting moiety for anti-RON ADC-directed drug delivery and anticancer therapy. Zt/g4-DM1 is highly effective alone or in combination with chemotherapeutics in inhibition of pancreatic cancer xenograft growth in preclinical models. These findings justify the use of humanized Zt/g4-DM1 for targeted pancreatic cancer therapy in the future.
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital of Zhejiang University School of MedicineHangzhou, China; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital of Zhejiang University School of MedicineHangzhou, China.
Hang-Ping
HP
Yao
Cancer Biology Research Center, Texas Tech University Health Sciences Center School of PharmacyAmarillo, TX 79106, USA; Department of Biomedical Sciences, Texas Tech University Health Sciences Center School of PharmacyAmarillo, TX 79106, USA.
Liang
L
Feng
Department of Molecular Cell Biology and Toxicology, Nanjing Medical University School of Public Health Nanjing, China.
Jian-Wei
JW
Zhou
Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center School of Pharmacy Amarillo, TX 79106, USA.
Rui-Wen
RW
Zhang
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital of Zhejiang University School of MedicineHangzhou, China; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital of Zhejiang University School of MedicineHangzhou, China; Cancer Biology Research Center, Texas Tech University Health Sciences Center School of PharmacyAmarillo, TX 79106, USA; Department of Biomedical Sciences, Texas Tech University Health Sciences Center School of PharmacyAmarillo, TX 79106, USA.
Ming-Hai
MH
Wang
Receptor tyrosine kinase; antibody-drug conjugate; combination therapy; pancreatic cancer; pharmacokinetics; therapeutic efficacy; xenograft tumor model